BioSpace

ESMO 2026: Marengo's bispecific antibody shrinks 8 tumor types in Phase 2

Invikafusp alfa, a first-in-class dual T cell agonist, showed an objective response in various types of cancer, particularly among patients who did not respond to previous checkpoint inhibitor therapy.

By BioSpace

1 min read
ESMO 2026: Marengo's bispecific antibody shrinks 8 tumor types in Phase 2
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights